Dual inhibition of glycolysis and autophagy as a therapeutic strategy in the treatment of Ehrlich ascites carcinoma

Keyphrases

• Therapeutic Strategies 100%
• Autophagy 100%
• Glycolysis Inhibition 100%
• Dual Inhibition 100%
• Ehrlich Ascites Carcinoma 100%
• Glycolysis 50%
• Salamae 50%
• Hydroxychloroquine 50%
• Group Treatment 25%
• Tumor 25%
• Cell Growth 25%
• In Cancer 25%
• Cancer Cells 25%
• Commercial Purpose 25%
• Self-use 25%
• Therapeutic Efficacy 25%
• Antioxidant Activity 25%
• Pathways in Cancer 25%
• Individual Treatment 25%
• Autophagy Inhibitor 25%
• Hexokinase 25%
• Cancer Cell Metabolism 25%
• Cancer Model 25%
• Antiglycolytic 25%
• Treatment Group 25%
• Oxidative Stress Status 25%
• Therapy Resistance 25%
• Redox Homeostasis 25%
• Preclinical Trials 25%
• Cell Count 25%
• Enhanced Antitumor Activity 25%
• Dual Targeting 25%
• Antitumor Activity 25%
• Model Trial 25%
• Protective Autophagy 25%

Medicine and Dentistry

• Autophagy 100%
• Ehrlich Ascites Tumor 100%
• Malignant Neoplasm 33%
• Cancer Cell 33%
• Antineoplastic Activity 33%
• Hydroxychloroquine 33%
• Combination Therapy 16%
• Cell Growth 16%
• Oxidative Stress 16%
• Therapy Resistance 16%
• Hexokinase 16%
• Cell Metabolism 16%
• Cell Count 16%
• Homeostasis 16%
• Cancer Model 16%
• Ascites Tumor 16%
• Antioxidant Capacity 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Ehrlich Ascites Tumor 100%
• Hydroxychloroquine 50%
• Antitumor Activity 50%
• Combination Therapy 25%
• Cancer Model 25%
• Therapy Resistance 25%
• Hexokinase 25%
• Ascites Tumor 25%
• Antioxidant Capacity 25%